Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
905 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04068181 | Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | completed | Phase 2 | 72 | AmgenINDUSTRY | 11 | Jan 7, 2025 | clinicaltrials |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | terminated | Phase 2 | 169 | MEI Pharma, Inc.INDUSTRY | 14 | Dec 31, 2024 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT02057380 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | completed | Phase 2 | 13 | Astellas Pharma Global Development, Inc.INDUSTRY | 7 | Nov 20, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | NantBioScience, Inc.INDUSTRY | 13 | Nov 8, 2024 | clinicaltrials |
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides(REDIRECT) | completed | Phase 2 | 108 | Affimed GmbHINDUSTRY | 10 | Nov 5, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT03427814 | Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer | completed | Phase 2 | 136 | BeiGeneINDUSTRY | 16 | Oct 26, 2024 | clinicaltrials |
| NCT05406401 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)(waveLINE-007) | active not recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Oct 15, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer(BOUNCE) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 5 | Oct 8, 2024 | clinicaltrials |
| NCT02281084 | Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes | completed | Phase 2 | 65 | CelgeneINDUSTRY | 10 | Oct 4, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT02855125 | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | completed | Phase 2 | 128 | Taiho Oncology, Inc.INDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04038359 | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma(TEMPO) | completed | Phase 2 | 103 | SecuraBioINDUSTRY | 8 | Sep 19, 2024 | clinicaltrials |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 1 | BioLineRx, Ltd.INDUSTRY | 6 | Sep 5, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT02965573 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | completed | Phase 2 | 24 | argenxINDUSTRY | 8 | Aug 28, 2024 | clinicaltrials |
| NCT03668119 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)(CheckMate 848) | completed | Phase 2 | 212 | Bristol-Myers SquibbINDUSTRY | 17 | Aug 28, 2024 | clinicaltrials |
| NCT02743221 | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy(TASCO1) | completed | Phase 2 | 154 | Institut de Recherches Internationales ServierOTHER | 12 | Aug 20, 2024 | clinicaltrials |
| NCT04204057 | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 21 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | Aug 13, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer(ESCAPE) | completed | Phase 2 | 23 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | terminated | Phase 1 / Phase 2 | 409 | PfizerINDUSTRY | 8 | Jul 30, 2024 | clinicaltrials |
| NCT01660451 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | completed | Phase 2 | 227 | BayerINDUSTRY | 25 | Jul 17, 2024 | clinicaltrials |
| NCT05593614 | Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)(ACT) | active not recruiting | Phase 2 | 276 | AlgoTherapeutixINDUSTRY | 7 | Jul 16, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | completed | Phase 2 | 61 | TakedaINDUSTRY | 6 | Jul 3, 2024 | clinicaltrials |
| NCT04677504 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | completed | Phase 2 | 162 | Hoffmann-La RocheINDUSTRY | 13 | Jul 3, 2024 | clinicaltrials |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)(STEREO) | terminated | Phase 2 | 6 | ETOP IBCSG Partners FoundationNETWORK | 8 | Jun 28, 2024 | clinicaltrials |
| NCT04731675 | An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee | completed | Phase 2 | 11 | AmMax Bio, Inc.INDUSTRY | 4 | Jun 27, 2024 | clinicaltrials |
| NCT06472583 | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer(BREAST-BOOSTER) | recruiting | Phase 2 | 78 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | completed | Phase 2 | 100 | Debiopharm International SAINDUSTRY | 9 | Jun 12, 2024 | clinicaltrials |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study(SECOMBIT) | completed | Phase 2 | 251 | Fondazione Melanoma OnlusOTHER | 10 | Jun 7, 2024 | clinicaltrials |
| NCT02937818 | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | completed | Phase 2 | 72 | AstraZenecaINDUSTRY | 5 | Jun 7, 2024 | clinicaltrials |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT04938180 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | terminated | Phase 2 | 4 | AmMax Bio, Inc.INDUSTRY | 3 | May 24, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT03711604 | Compassionate Use Study of Tenalisib (RP6530) | completed | Phase 1 / Phase 2 | 17 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | May 8, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials